FDA_TrackerJim said:Keep the original post as written when you update it, and add the correction underneath.
This is exactly what I could not find anywhere else.
Adding the clinical framing, because it changes how the question reads. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.
LibrarianMeg said:Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…
Second this. The detail I would add is minor and it is already implied above.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemLibrarianMeg said:Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…
Coming at LibrarianMeg’s question from a different direction. The pattern that distinguishes a bad batch from an exit is behaviour rather than product. A bad batch comes with communication, a reshipment offer and a batch number. An exit comes with slower replies, pressure toward less reversible payment methods, sudden discounting, and the same reassurance repeated without any new information. The product tells you less than the correspondence does.
Correct me if the detail matters more than I have assumed.
OP back with an update, since a thread like this is useless without one.
Closing the loop. The answer turned out to depend on the detail I had left out of the opening post, which is a lesson about how to ask rather than about the subject.